3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
The effects are often described as being more euphoric and mentally clearer than many related compounds.
A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.
Most if not all consumer-grade jewelry-scales advertised as working at the 0.001g (mg) range are not reliably accurate enough to measure quantities weighing less than around 15-25 mg depending on the model and calibration.
With a drug as potent as 3-MeO-PCP a small discrepancy in measurement can make a world of difference in physical and mental response to the dose.
It is for these reasons that it would be in one's best interest to use a volumetric dose measurement technique as outlined in this guide.
|| 1.5-3 mg
|| 3-5 mg
|| 5-8 mg
|| 8-12 mg
|| 20-40 minutes
|| 4-6 hours
|| 2-48 hours
Insufflated onset is approximately 5-15 minutes and the duration is a bit shorter.
- Increase in energy / stimulation
- Pleasant mental and/or body high
- Increased sociability, loss of inhibitions
- Closed and open-eye visuals
- Shifts in perception of reality
- Increased heart rate (lower doses)
- Disrupted speech patterns
- Analgesia (decreased pain awareness) and numbness
- Distorted sensory perceptions, hallucinations
- Unusual and unpredictable behavior
- Mild to moderate dissociation
- Confusion, disorientation
- Disturbing hallucinations and/or delusions
- Severe dissociation, depersonalization
- AtaxiaLoss of motor coordination (loss of motor coordination)
- Severe distortion or loss of auditory/visual perception
- 3-Meo-PCP is a very powerful NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. antagonistA substance that interferes with or inhibits the physiological action of another. (doses are on par with PCP), and as such it has the potential to be very confusing.
- 3-MeO-PCP is considered to be a 'research-chemical', simply meaning that there is little to no clinical data on long-term effects.
- 3-MeO-PCP, as with all arylcyclohexylamineA class of dissociatives, which includes PCP, Ketamine, Methoxetamine and others. An arylcyclohexylamine is composed of a cyclohexylamine unit with an aryl moiety attachment. The aryl group is positioned geminal to the amine. In the simplest cases, the aryl moiety is typically a phenyl ring, sometimes with additional substitution. The amine is usually not primary, secondary amines such as methylamino or ethylamino, or tertiary cycloalkylamines such as piperidino and pyrrolidino, are the most commonly encountered N-substituents. class dissociative compounds may cause neurotoxicity when used frequently or in high dose.
- 3-MeO-PCP acts as a mild SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Reuptake Inhibitor and as such may risk adverse effects as a result of synergy when used with certain serotogenic drugs or medications. See Interactions.
- It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See the dosage section for more information.
- 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.
For more information see Dissociative Harm-Reduction.
Check out our Drug Combinations page and chart for interactions and combinations of common drugs.
PCP and 3-MeO-PCP have similar profiles and as such its safe to assume the PCP combination-chart data also applies to 3-MeO-PCP.
Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.
Chemistry and Pharmacology
3-MeO-PCP binds to the NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Reuptake Inhibitor (SRISerotonin Reuptake Inhibitor).
3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.
3-MeO-PCP has a Ki of 20 nM for the NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor, 216 nM for the serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. transporter and 42 for the sigma1 receptor.
UK: Class B, as are all arylcyclohexamines.
US: Covered by the analogue act if sold for human consumption.
Interview with a Ketamine Chemist
From MXE to PCP